AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05636514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
Description: Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
Study NCT05636514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily
Study NCT04376242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: use of virtual reality
Description: The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
Study NCT04376242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of virtual reality
Description: The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
Study NCT04376242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: use of standard technology
Description: the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
Study NCT04376242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of standard technology
Description: the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
Study NCT06075654 — intervention group
Intervention type: OTHER
Intervention: no intervention it is considered (Epidemiological Study)
Description: It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
Study NCT05665608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs.
Study NCT05665608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Study NCT05665608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Study NCT04662723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: To reduce the progression of renal damage in IgAN Patients
Study NCT04662723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: To reduce the progression of renal damage in IgAN Patients
Study NCT04662723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin sytem blockers
Description: To reduce the progression of renal damage in IgAN Patients
Study NCT04662723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin-angiotensin sytem blockers
Description: To reduce the progression of renal damage in IgAN Patients
Study NCT04662723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitor
Description: To reduce the progression of renal damage in IgAN Patients
Study NCT06165237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6001-1
Description: One tablet administered alone, Once a day
Study NCT06165237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6001-2
Description: One tablet administered alone, Once a day
Study NCT04806321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project SOLVE
Description: This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.
Study NCT04806321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Project SUCCESS
Description: This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
Study NCT05621850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
Study NCT05621850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
Study NCT06056453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: IPT group-virtual
Study NCT06117553 — intervention group
Intervention type: PROCEDURE
Intervention: thorough flushing
Description: The thorough flushing strategy refers to the thorough flushing of all liquid and foam accumulation areas during the inspection. Make all liquid accumulation parts in the intestinal cavity free of aspiratable liquid retention
Study NCT04408664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate
Description: Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
Study NCT04408664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
Study NCT04993872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy Tab
Description: Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
Study NCT04140721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo pill identical to moxonidine administered for 4 weeks
Study NCT04140721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine Pill
Description: Moxonidine pill administered for 4 weeks
Study NCT06192238 — intervention group
Intervention type: PROCEDURE
Intervention: adrenal venous sampling
Description: Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Study NCT06277570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.
Study NCT06277570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: Neuromuscular Electrical Stimulation (NMES) is a non-invasive method that activates intramuscular nerve branches and produces visible contractions through surface electrodes placed on skeletal muscles.
Study NCT06277570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Superimposed NMES
Description: Superimposed NMES technique is the use of NMES with voluntary muscle contraction.
Study NCT05136079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic lymphaticonvenous anastomosis
Description: Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
Study NCT05208827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
Study NCT05208827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo(not contain vitamin D)
Description: Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
Study NCT05028829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Oral administration of atorvastatin 20 mg
Study NCT05028829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo
Study NCT05082337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAVVY guidewire
Description: The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
Study NCT04697290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 Dual-CAR-T cells
Description: CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
Study NCT05298683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
Study NCT05298683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
Study NCT05298683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
Study NCT05298683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Description: Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
Study NCT05298683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine (or equivalent)
Description: Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
Study NCT05298683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (or equivalent)
Description: Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
Study NCT06508060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosensory Wristband
Description: The Neosensory wristband consists of four vibratory motors built into the strap of the wristband (Figure 1a). The motors are linear resonant actuators (LRAs), vibrating at 175 Hz, capable of rising from 0 to 50% of their intensity within 30 ms. The motor intensity can be controlled with an eight bit resolution, meaning each motor can be controlled at 256 different intensities. At the highest intensity, each motor vibrates at 1.7 GRMS. The motors are separated from one another at a distance of 18.2 mm and 19.2 mm for the small and large wristband sizes, respectively (center-to-center distances).~The top of the wristband is a module that contains the power button, user setting buttons, a microphone, and a microcontroller. Bluetooth communication is used to create the corresponding vibrations on the wristband. While the study app plays the tones, it also sends a Bluetooth command to the wristband such that the wristband vibrates in the appropriate illusory location.
Study NCT06508060 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tones only
Description: Tones will be played through an app
Study NCT05565170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured ICT-assisted multimodal lifestyle intervention
Description: The structured lifestyle intervention programme, partly tailored and personalised to individual needs, covers the following domains: physical activity, nutrition, cognitive activity, cardiovascular risk management, social interaction, sleep, and relaxation / stress management. The programme includes regular scheduled in-person sessions (group-based + individual) which are supported with independent digital activities in the LETHE App. The App has features such as e.g., a cognitive training programme, on-demand exercise videos, calendar to schedule activities, advice and educational material, group chat, and possibility to set and monitor goals and self-monitor risk factors such as e.g., blood pressure.
Study NCT05565170 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-guided multimodal lifestyle intervention
Description: Participants are advised to build their own healthy lifestyle programme based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits and through the simplified version of the LETHE app. The control group app does not include any structured / scheduled activities or personalised content.
Study NCT05259423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Education Program
Description: Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
Study NCT05259423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Education Program
Description: Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
Study NCT06189859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic submucosal dissection using SPRAY COAG mode
Description: After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Spray coag mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
Study NCT06189859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic submucosal dissection using Precisect mode
Description: After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Precisect mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
Study NCT06112353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine Injectable Solution
Description: Examine GI-2 recovery
Study NCT06112353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex injection
Description: Examine GI-2 recovery
Study NCT05953155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.
Study NCT05953155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
Study NCT06003075 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab and Chemotherapy
Description: 3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks
Study NCT06003075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation
Study NCT06003075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Induction Surgery
Description: Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles
Study NCT05988944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TT+CIMT+VR
Description: TT: Traditional Techniques CIMT: constraint-induced movement therapy VR: virtual reality
Study NCT05988944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TT+CIMT
Description: TT: Traditional Techniques CIMT: constraint-induced movement therapy
Study NCT05988944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TT
Description: TT: Traditional Techniques
Study NCT04836169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InCaveo's EOA system with integrated mobile CBT
Description: integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
Study NCT05796492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed splenic ultrasound
Description: A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
Study NCT05796492 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound probe (no energy applied)
Description: A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
Study NCT05022459 — intervention group
Intervention type: DRUG
Intervention: Emicizumab
Description: Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
Study NCT05022459 — intervention group
Intervention type: DRUG
Intervention: FVIII
Description: Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
Study NCT05495932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
Study NCT05144321 — intervention group
Intervention type: OTHER
Intervention: Impact of environment upon obstetrical
Description: Impact of environment upon obstetrical
Study NCT05144321 — intervention group
Intervention type: OTHER
Intervention: neonatal and maternal adverse outcome
Description: neonatal and maternal adverse outcome
Study NCT06003075 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post Induction XRT
Description: Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.
Study NCT06304480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100g fermented Tofu
Description: * Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.~* Participants will consume the first Study Product on the day of their Visit 3 (Day 0) and will consume their last Study Product the day prior to Visit 5 (Day 56).~* Participants will be instructed to return any unused Study Product at Visit 5 (Day 56).
Study NCT05463588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercising with virtual reality glasses
Description: GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training